As previously reported, BofA upgraded Rocket Pharmaceuticals (RCKT) to Buy from Neutral with a price target of $10, up from $4, after the FDA lifted the clinical hold on the company’s Phase 2 trial of RP-A501 for the treatment of Danon disease. Rocket’s restructuring had suggested the process to have the hold lifted would be “lengthy,” so today’s news is “positive surprise” that removes a key overhang and sets up a path to shares re-rating, the analyst tells investors. Following the update, the firm is increasing its view on the odds of success for ‘A501 to 50% from 15%, while maintaining its “more conservative” 2028 launch assumption.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals upgraded to Buy from Neutral at BofA
- Citi says FDA may take ‘more comprehensive look’ at Sarepta Elevidys adjustment
- Target names CEO successor, Guess to go private: Morning Buzz
- Rocket alignment with FDA ‘sounds reasonable,’ says Chardan
- Cautious Optimism: Hold Rating on Rocket Pharmaceuticals Amid Resumed Phase II Study with Protocol Changes